Halozyme (HALO -0.2%) reports that the target number of 330 overall survival (OS) events has been reached in the Phase 3 HALO-301 study evaluating lead candidate PEGPH20 for the first-line treatment of metastatic pancreatic cancer. The primary endpoint is OS.
Data maturity should be reached in mid-September, followed the announcement of topline results by December.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.